Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vanda Pharmaceuticals, a developer of products for central nervous system disorders, has selected Probiomed, the pharmaceutical operating unit of Proquifin, as its new commercialization partner for schizophrenia drug Fanapt in Mexico.
Subscribe to our email newsletter
As per the terms of the agreement, Probiomed is responsible for seeking regulatory approval for Fanapt in Mexico.
However, Vanda will be responsible for supplying the drug to Probiomed for promoting and selling the drug.
Probiomed founder and CEO Jaime Uribe de la Mora said theye expect to submit the regulatory dossier for market authorization review by the end of 2011.